The application was accepted under priority review status, according to the Cambridge, Mass.-based company. If approved, the drug would be the first therapy specifically indicated to treat postpartum depression – the most common medical complication of childbirth.
The company’s drug is an allosteric modulator of synaptic and extrasynaptic GABA-A receptors. As an allosteric modulator, it works to indirectly regulate the activity of neurotransmitter receptors, rather than simply turning them on or off.
Sage’s NDA included data from two Phase III trials that evaluated the safety and efficacy of brexanolone in women ages 18 to 45 with moderate and severe postpartum depression. At all doses in both trials, brexanolone demonstrated a significant mean reduction from baseline in the Hamilton Rating Scale for Depression score after 60 hours compared to placebo. The most common adverse events across all treatment groups were headache, dizziness and somnolence, according to Sage.
Because Sage’s drug is a new molecular entity with a new mechanism of action, the FDA plans to hold an advisory committee meeting to discuss the company’s application. The regulatory agency is slated to make a decision regarding Sage’s NDA by December 19.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.